CME 10 Session - EANM'14

Paediatrics & Oncology: Therapy Response Monitoring in Paediatric Oncology

Educational objectives:

  1. To explain the role of individualised treatment in paediatric malignancies
  2. To characterise the current and future place of metabolic imaging in treatment optimisation protocols of different paediatric malignancies
  3. To compare strengths and weaknesses of established and new radiotracers for imaging and response assessment in neuroblastoma
  4. To define criteria for evaluation of interim PET in Hodgkin’s lymphoma and explain the changes in the current European treatment optimisation protocol for paediatric Hodgkin’s lymphoma
This session focuses on paediatric oncology reaching out towards all physicians interested in nuclear oncology in special malignancies. Firstly, the paediatric oncologist will give an overview of late effects caused by radiotherapy and chemotherapy for Hodgkin lymphoma during childhood and adolescence. Possibilities to reduce these sequels without compromising cure rates will be analysed. Thereafter, the current and potential input of functional imaging methods to identify the individual response early during treatment will be reviewed for different paediatric malignancies. Children with cancer are generally treated within large multicentre protocols. The role of nuclear medicine methods in these protocols will be highlighted. In paediatric Hodgkin’s lymphoma F-18-FDG-PET is widely used for initial staging and early response assessment after 2 cycles of chemotherapy. Patients with adequate response will receive reduced treatment intensity with less or no radiotherapy. In 2014, the new EuroNet-PHL-C2 trial will be started. The new diagnostic algorithms and criteria for response assessment will be presented. Neuroblastoma is a neuroendocrine tumour, arising from a neural crest element of the sympathetic nervous system showing a heterogeneous uptake pattern for different radiotracers like the longtime standard I-123-MIBG or PET-tracers like F-18-DOTATOC, F-18-DOPA or F-18-FDG. The current knowledge about strength and weaknesses of these radiotracers in the response assessment of neuroblastoma will be reviewed.

Key Words:
Treatment Individualisation, Hodgkin's Lymphoma, Neuroblastoma
Teaser Video
A short description by Francesco Giammarile, chair of the EANM Oncology Committee

User action required
If you have the permission to view this publication, please log in.